Bai Yu, Wang Yong-Lian, Yao Wen-Jian, Guo Ling, Xi Hui-Fang, Li Song-Yue, Zhao Bao-Sheng
Department of Pathology, Xinxiang Medical University Xinxiang 453000, China.
Department of Thoracic Surgery, The First Affiliated Hospital of Xinxiang Medical University Weihui 453100, China.
Int J Clin Exp Pathol. 2015 Jan 1;8(1):824-9. eCollection 2015.
miR-32 has recently been found to be implicated in many critical processes in various types of human cancer. However, its clinical significance in human non-small cell lung cancer (NSCLC) has not yet been elucidated. In the present study, we investigated the expression of miR-32 in NSCLC and analyzed its association with clinical features and prognosis of NSCLC patients.
Quantitative real-time PCR (qRT-PCR) was used to measure expression level of miR-32 in lung cancer cell lines, normal bronchial epithelial cells, 90 pairs of tumor samples and adjacent non-tumor tissues. To determine its prognostic value, overall survival was evaluated using the Kaplan-Meier method. Univariate and multivariate analysis were performed using the Cox proportional hazard analysis.
The expression of miR-32 was significantly decreased in lung cancer cell lines and NSCLC tissues compared with normal bronchial epithelial cells and adjacent non-tumor tissues (P < 0.05). This reduction of miR-32 was associated with tumor stage and lymph node metastasis (P < 0.05). Moreover, Kaplan-Meier analysis demonstrated that patients with low miR-32 expression had shorter overall survival time than those with high miR-32 expression (P < 0.05). Univariate analysis revealed statistically significant correlations between overall survival and miR-32 level, tumor stage and lymph node metastasis (P < 0.05). Furthermore, miR-32 levels, tumor stage and lymph node metastasis were independently associated with overall survival (P < 0.05).
Our results provided the first evidence that down-regulation of miR-32 was correlated with NSCLC progression, and miR-32 might be a potential molecular biomarker for predicting the prognosis of patients.
最近发现miR-32参与多种类型人类癌症的许多关键过程。然而，其在人类非小细胞肺癌（NSCLC）中的临床意义尚未阐明。在本研究中，我们调查了miR-32在NSCLC中的表达，并分析了其与NSCLC患者临床特征及预后的关系。
采用定量实时聚合酶链反应（qRT-PCR）检测肺癌细胞系、正常支气管上皮细胞、90对肿瘤样本及癌旁非肿瘤组织中miR-32的表达水平。为确定其预后价值，采用Kaplan-Meier法评估总生存期。使用Cox比例风险分析进行单因素和多因素分析。
与正常支气管上皮细胞和癌旁非肿瘤组织相比，肺癌细胞系和NSCLC组织中miR-32的表达显著降低（P<0.05）。miR-32的这种降低与肿瘤分期和淋巴结转移相关（P<0.05）。此外，Kaplan-Meier分析表明，miR-32低表达患者的总生存时间短于miR-32高表达患者（P<0.05）。单因素分析显示总生存期与miR-32水平、肿瘤分期和淋巴结转移之间存在统计学显著相关性（P<0.05）。此外，miR-32水平、肿瘤分期和淋巴结转移与总生存期独立相关（P<0.05）。
我们的结果首次证明miR-32的下调与NSCLC进展相关，且miR-32可能是预测患者预后的潜在分子生物标志物。
